
    
      Subjects who were still receiving treatment with guadecitabine and in the opinion of the
      investigator were still benefitting from treatment at the time of database close of the
      original study will be eligible to participate in this extension study. Approximately 250
      subjects could be enrolled.

      Subjects will attend clinic visits on Days 1-5 of each 28-day cycle to receive treatment with
      guadecitabine. Data collection will be limited to treatment exposure, adverse events,
      concomitant medications, limited laboratory parameters, and survival status.
    
  